Transient hypogammaglobulinemia of infancy
MONDO:0015698A rare, primary humoral immunodeficiency of childhood characterized by decreasing serum levels of immunoglobulin G (IgG) as maternal antibodies clear the circulation while serum levels of immunoglobulin A and immunoglobulin M remain normal or are slightly decreased. Diagnosis may be suspected after the age of six months when a child's own synthesis of IgG should accelerate but it must be confirmed retrospectively after normalization of all serum immunoglobulin levels is seen by ages 2-6. This disorder may be caused by inadequate activation of progenitor B cells, defective class-switching or may even represent a maturational variant. Typically, a normal response to protein antigens is found while there is a notably diminished response to viral and bacterial polysaccharide antigens. Clinical presentation may include recurrent infections especially those of the respiratory tract. Despite increased susceptibility to infection in childhood, this disorder is self-limited with minimal implications for a normal life span.
Also known as: THI, transient hypogammaglobulinemia of infancy
41 clinical trials for this condition and its sub-types, 0 tagged with Transient hypogammaglobulinemia of infancy itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
New shot could help Immune-Compromised patients fight infections
Disease control OngoingThis phase 3 trial is testing a new medicine called Newnorm, a concentrated antibody solution given as a shot under the skin, in 50 people with primary immunodeficiency (a condition where the immune system doesn't work properly). The goal is to see if Newnorm can prevent serious …
Phase 3 • Sponsor: Octapharma • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New antibody therapy aims to shield kids with rare immune disease from deadly infections
Disease control OngoingThis study tests a medicine called Kedrion IVIG 10% in 30 children with primary immunodeficiency, a condition where the immune system doesn't work properly. The treatment is made from donated antibodies and is given through a vein to help prevent serious bacterial infections. Res…
Phase 3 • Sponsor: Kedrion S.p.A. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Quick-Push immune therapy studied for safety and ease
Disease control OngoingThis study looks at whether giving Cutaquig® (a medicine that helps fight infections) by a faster manual push method is safe and easy for adults with primary or secondary immunodeficiency. About 36 participants will use the rapid push method at home. The goal is to see if this ap…
Sponsor: University of Alberta • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New antibody therapy tested for long-term safety in immune-deficient patients
Disease control OngoingThis study tests the long-term safety of TAK-881, a subcutaneous immunoglobulin treatment, in 53 adults and children with primary immunodeficiency diseases (PIDD) who completed a prior study. Participants receive regular infusions every 2-4 weeks and are monitored for side effect…
Phase 3 • Sponsor: Takeda • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Scientists collect skin cells to pave way for future immune disease cures
Knowledge-focused By invitation onlyThis study collects small skin samples from people with primary immunodeficiency or immune regulation disorders, as well as from healthy volunteers. Researchers will use these cells to create cell lines for laboratory research. The goal is to better understand immune diseases and…
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Sep 02, 2026 00:00 UTC